Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review

References

• Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61((S)3):iii8–18.
   PubMedGoogle Scholar
• Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatol. 2014;53:650–657.
   PubMed Web of Science ®Google Scholar
• Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):369–389.
   PubMed Web of Science ®Google Scholar
• Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis. 2010;69:579–581.
   PubMed Web of Science ®Google Scholar
• Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality. Ann Intern Med. 2015;163(6):409.
   PubMed Web of Science ®Google Scholar
• Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res. 2011;63:557–563.
   PubMed Web of Science ®Google Scholar
• Patel SA, Winkel M, Ali MK, et al. Cardiovascular mor- tality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163:245–253.
   PubMed Web of Science ®Google Scholar
• Schieir O, Tosevski C, Glazier RH, et al. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis. 2017;76:1396–1404.
   PubMed Web of Science ®Google Scholar
• Maia DG, Augusto KL, Bezerra MC, et al. Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk. Clin Rheumatol. 2017;36(10):2371–2376.
   PubMed Web of Science ®Google Scholar
• Malesci D, Niglio A, Mennillo GA. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheum. 2007;26:710–714.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ko GTC, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res. 2011;63:195–202.
   PubMed Web of Science ®Google Scholar
• Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016;75:1016–1023.
   PubMed Web of Science ®Google Scholar
• Moltó A, Nikiphorou E. Comorbidities in spondyloarthritis. Front Med. 2018;5:62.
   Web of Science ®Google Scholar
• Derakhshan MH, Goodson NJ, Packham JC, et al. BRITSpA and COMOSPA investigators. increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPa study. J Rheumatol. 2019 Jan 15;46:701–709. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11:693–704.
   PubMed Web of Science ®Google Scholar
• Mureddu GF, Brandimarte F, De Luca L. High-density lipoprotein levels and risk of cardiovascular events: a review. J Cardiovasc Med. 2012;13:575–586.
   Google Scholar
• Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci. 2005;109:171–176.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Markatseli TE, Saougou I, et al. Kiortsis DN5, drosos AA6. Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine. 2014;81(1):57–63.
   PubMed Web of Science ®Google Scholar
• Peters MJ, van der Horst-bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particuarly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34:585–592.
   PubMed Web of Science ®Google Scholar
• López-Medina C, Jiménez-Gómez Y, Moltó A, et al. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: an ancillary study of the ASAS-COMOSPa project. Joint Bone Spine. 2018;85:447–453.
   PubMed Web of Science ®Google Scholar
• Chou CH, Lin MC, Peng CL, et al. A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol. 2014;43:132–136.
   PubMed Web of Science ®Google Scholar
• Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550–556.
   PubMed Web of Science ®Google Scholar
• Han C, Robinson DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167–2172.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991.
   PubMed Web of Science ®Google Scholar
• Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis. 2013;72:1430–1432.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388–1398.
   PubMed Web of Science ®Google Scholar
• Chung HY, Machado P, van der Heijde D, et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis. 2012;71:809–816.
   PubMed Web of Science ®Google Scholar
• Jones GT, Ratz T, Dean LE, et al. Disease severity in never smokers, ex-smokers, and current smokers with axial spondyloarthritis: results from the Scotland registry for ankylosing spondylitis. Arthritis Care Res. 2017;69(9):1407–1413.
   Web of Science ®Google Scholar
• Glintborg B, Hoigaard P, Hetland M, et al. Impact of tobacco smoking on response to tumor necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology. 2016;55:659–668.
   PubMed Web of Science ®Google Scholar
• Bai R, Zhang Y, Liu W, et al. The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis. Angiology. 2019;70(6):492–500.
   PubMed Web of Science ®Google Scholar
• Arida A, Protogerou AD, Konstantonis G, et al. Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and meta-analysis of published studies. J Rheumatol. 2015;42:2098–2105.
   PubMedGoogle Scholar
• Berg J, van der Heijde D, Dagfinrud H, et al. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol. 2015;42(4):645–653.
   PubMed Web of Science ®Google Scholar
• Avram C, Drăgoi RG, Popoviciu H, et al. Association between arterial stiffness, disease activity and functional impairment in ankylosing spondylitis patients: a cross-sectional study. Clin Rheumatol. 2016;35(8):2017–2022.
   PubMed Web of Science ®Google Scholar
• Cure E, Icli A, Ugur A, et al. Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis. Clin Rheumatol. 2018;37:1273.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Peraldi P, Budavari A, et al. SpiegelmanBM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665–668.
   PubMed Web of Science ®Google Scholar
• Capkin E1, Karkucak M, Kiris A, et al. Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology. 2012;51(5):910–914.
   PubMed Web of Science ®Google Scholar
• van Eijk IC, Peters MJ, Serné EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68(3):362–366.
   PubMed Web of Science ®Google Scholar
• Syngle A, Vohra K, Sharma A, et al. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol. 2010;29(7):763–770.
   PubMed Web of Science ®Google Scholar
• Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology. 2013;52(1):204–209.
   PubMed Web of Science ®Google Scholar
• Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine. 2010;77(1):50–52.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN1, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(5):921–923.
   PubMed Web of Science ®Google Scholar
• Spanakis E1, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33(12):2440–2446.
   PubMed Web of Science ®Google Scholar
• Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007;66(11):1503–1507.
   PubMed Web of Science ®Google Scholar
• Van Sijl AM, van Ejik IC, Peters MJL, et al. Tumor necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheumatic Dis. 2015;74:119–123.
   PubMed Web of Science ®Google Scholar
• Zardi EM, Pipita ME, Giorgi C, et al. Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-α antagonists and healthy matched controls. Medicine (Baltimore). 2018;97(27):e11250.
   PubMed Web of Science ®Google Scholar
• Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies. Hypertension. 2010;55(2):333–338.
   PubMed Web of Science ®Google Scholar
• Arida A, Athanasios D, Protogerou AD, et al. Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and meta-analysis of published studies. J Rheumatol. 2015;42(11):2098–2105.
   PubMedGoogle Scholar
• Genre F, López-Mejías R, Miranda-Filloy JA, et al. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.. Rheumatol Int. 2015;35(12):2069–2078.
   Web of Science ®Google Scholar
• Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33:2440–2446.
   PubMed Web of Science ®Google Scholar
• van Eijk IC, De Vries MK, Levels JHM, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum. 2009;60:1324–1330.
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga M, Kneepkens EL, et al. The effects of 5-year etanercept therapy on cardiovascular risk factors in patients with psoriatic arthritis. J Rheumatol. 2017;44:136–138.
   PubMedGoogle Scholar
• Brewerton DA, Gibson DG, Goddard DH, et al. The myocardium in ankylosing spondylitis. A clinical, echocardiographic, and histopathological study. Lancet. 1987;1:995–998.
   PubMed Web of Science ®Google Scholar
• Brunner F, Kunz A, Weber U, et al. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol. 2006;25:24–29.
   PubMed Web of Science ®Google Scholar
• Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese society of echocardiography. J Am Soc Echocardiogr. 2011;24:277–313.
   PubMed Web of Science ®Google Scholar
• Biesbroek PS, Heslinga SC, Konings TC, et al. Insights into cardiac involvement in ankylosing spondylitis from cardiovascular magnetic resonance. Heart. 2017;103(10):745–752.
   PubMed Web of Science ®Google Scholar
• Bansal M, Cho GY, Chan J, et al. Feasibility and accuracy of different techniques of two-dimensional speckle-based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21:1318–1325.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005;4:153–161.
   PubMed Web of Science ®Google Scholar
• Fontes JA, Rose NR, Čiháková D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74:62–68.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Gianturco L, Bongiovanni S, et al. Non-invasive imaging methods of evaluating cardiovascular parameters in patients with ankylosing spondylitis before and after 12-month treatment with anti-TNF drugs. J Bio Homeost Agents. 2016;30:1.
   Google Scholar
• Helslinga SC, Van den Oever IA, van Sijl AM. Van den Oever IA Van Sijl AM, Peters MJ, Van der Horst-Bruinsma IE, Smulders YM, Nurmohamed MT Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015;16:80.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol. 2014;63:2985–3023.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Atherosclerosis. 2016;252:207–274.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Voulgari P, Drosos A. Cardiovascular disease in spondyloarthritides. Curr Vasc Pharmacol. 2019 May 16. Epub ahead of print. doi: 10.2174/1570161117666190426164306.
   PubMedGoogle Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28.
   PubMed Web of Science ®Google Scholar